BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure
Rhea-AI Summary
BioCardia (Nasdaq: BCDA) submitted CardiAMP HF clinical study data and requested an FDA meeting to discuss an accelerated approval pathway for the CardiAMP System in ischemic HFrEF. The meeting is expected this quarter under the device's Breakthrough Designation.
Key data: 125 ischemic HFrEF patients enrolled; subgroup with elevated heart-stress biomarkers showed a 47% relative reduction in all-cause cardiac death, 37% relative reduction in non-fatal major adverse cardiac events, and quality-of-life improvement (p=0.04). Results were presented at THT 2026.
Positive
- Breakthrough Designation meeting request with FDA during the quarter
- Clinical dataset includes 125 ischemic HFrEF patients
- Subgroup: 47% RRR in all-cause cardiac death
- Subgroup: 37% RRR in non-fatal major adverse cardiac events
- Quality-of-life improvement reported (p=0.04)
Negative
- No FDA approval yet; company requested a meeting to discuss accelerated pathway
- Reported benefits confined to a subgroup with elevated biomarkers, not entire trial population
Key Figures
Market Reality Check
Peers on Argus
BCDA fell 4.13% while momentum peers were mixed: PHGE appeared up about 14.24% and BRTX down about 5.37%. With gains and losses across peers and no same‑day peer news, today’s move looks more stock‑specific than sector‑driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Earnings update | Negative | -0.4% | Reported 2025 net loss of about $8.2M and limited cash position. |
| Mar 19 | Conference call | Neutral | +0.0% | Announcement of scheduled 2025 results call and corporate update webcast. |
| Mar 17 | FDA pre-submission | Positive | +0.8% | FDA accepted Helix catheter pre‑submission, with review and meeting set for early Q2. |
| Mar 03 | Clinical data update | Positive | -5.9% | Phase III CardiAMP HF subgroup showed significant LV volume improvements at THT. |
| Feb 10 | Regulatory filing | Positive | -0.8% | Pre‑Submission filed to FDA for Helix catheter with data from 15 trials. |
Recent history shows mixed reactions: regulatory and clinical positives sometimes aligned with small gains but also drew selloffs, indicating no consistent pattern on news flow.
Over recent months, BioCardia has focused on advancing its CardiAMP and Helix programs through FDA interactions and late‑stage data readouts. Key events included a Helix pre‑submission acceptance, Phase III CardiAMP HF echocardiography results, and multiple 8‑K disclosures around these updates, alongside 2025 financials showing continued net losses and limited cash. Today’s accelerated approval meeting request builds directly on the CardiAMP HF trial subgroup benefits and prior THT presentations, extending the same regulatory narrative.
Market Pulse Summary
This announcement highlights BioCardia’s attempt to leverage CardiAMP HF trial data, especially in a high‑risk subgroup, to pursue an FDA accelerated approval pathway. The reported 47% reduction in all‑cause cardiac death, 37% reduction in non‑fatal major adverse events, and quality‑of‑life improvement at p=0.04 build on prior THT presentations. Investors should watch the scheduled FDA meeting’s feedback, subsequent regulatory filings, and how these align with BioCardia’s limited cash resources and ongoing development-stage losses.
Key Terms
accelerated approval pathway regulatory
breakthrough designation regulatory
HFrEF medical
myocardial infarction medical
AI-generated analysis. Not financial advice.
SUNNYVALE, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported submission to United States Food and Drug Administration (FDA) of the CardiAMP HF clinical study data and on its plans to meet with the FDA to discuss the accelerated approval pathway for the CardiAMP® System for ischemic chronic heart failure with reduced ejection fraction (HFrEF).
This meeting request is in line with previous guidance and BioCardia expects to have the meeting during this quarter. The meeting will be held under BioCardia’s FDA Breakthrough Designation for the CardiAMP System.
The key objectives of the meeting are to obtain FDA feedback on the acceptability of BioCardia’s proposed submission for approval based on the safety seen in the CardiAMP HF Trial, the well-characterized clinical response data for the 125 ischemic HFrEF patients enrolled into the trial, and the low risk and high potential benefit profile in the subgroup with elevated biomarkers of heart stress participating in the trial.
For the CardiAMP HF trial subgroup with elevated biomarkers of heart stress, the cells delivered have shown meaningful benefit for these higher-risk patients already on stable American Heart Association and American College of Cardiology guideline directed medical therapy. Demonstrated benefits in the subgroup, in addition to benefits the patients received from guideline directed medical therapy over two years, include an additional
About CardiAMP Autologous Cell Therapy
Granted FDA Breakthrough designation, CardiAMP Cell Therapy uses a patient’s own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure intended to increase capillary density and reduce tissue fibrosis of myocardial tissue to address microvascular dysfunction. Clinical development of the CardiAMP Cell Therapy for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by Centers for Medicare and Medicaid Services (CMS). CAUTION - Limited by United States law to investigational use.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information visit www.biocardia.com.
Forward Looking Statements:
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements relating to FDA approval of CardiAMP, the planned meeting and the likelihood of safety and patient benefit. These forward-looking statements are made as of the date of this press release.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully progress its clinical trials. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Media Contact:
Miranda Peto, Marketing / Investor Relations
Email: mpeto@BioCardia.com
Phone: 650-226-0120
Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120
FAQ
What did BioCardia (BCDA) file with the FDA on April 2, 2026 regarding CardiAMP?
How many patients were enrolled in the CardiAMP HF trial reported by BioCardia (BCDA)?
What efficacy results did BioCardia (BCDA) report for the elevated-biomarker subgroup?
When will BioCardia (BCDA) meet the FDA to discuss CardiAMP accelerated approval?
Where were the latest CardiAMP HF trial results from BioCardia (BCDA) presented?
